Homocysteine and ischemin heart disease: Results of a prospective study with implication regarding prevention

Archives of Internal Medicine

Volumn 158, Issue 8, 1998, Pages 862-867

  Wald, Nicholas J ^a   Watt, Hilary C ^a   Law, Malcolm R ^a   Weir, Donald G ^b   McPartlin, Joseph ^b   Scott, John M ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; HEART MUSCLE ISCHEMIA; META ANALYSIS; MIDDLE AGED; RISK; RISK FACTOR;

ADULT; CASE-CONTROL STUDIES; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ODDS RATIO; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032571596     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.8.862     Document Type: Article

References (63)

1. McCully KS. Vascular pathology of homocyst(e)inemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
2. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis. 1988;71:227-233.
3. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
4. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
5. Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr. 1991;69:527-534.
6. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine. folate, and vitamin B-12 concentrations and risk for early onset coronary artery disease. Am J clin Nutr. 1994;59:940-948.
7. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
8. Dalery K, Lusster-Cocan S, Selhub J, Davignon J, Latour Y, Genest J. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6. pyridoxal phosphate, and folate. Am J Cardiol. 1995;75:1107-1111.
9. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol. 1996;143:845-859.
10. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995; 274:1049-1057.
11. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet. 1997;349:397.
12. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709
13. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA. 1992;268: 877-881.
14. Alfthan G, Pekkanen J, Juahianen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
15. Evans RW, Shaten J, Hempel JD, Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscier Thromb Vase Biol. 1997;17:1947-1953.
16. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocysteine and risk of ischémic stroke. Stroke. 1994; 25:1924-1930.
17. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma homocysteine and risk of angina pectoris: results from a prospective study. Ir J Med Sci. 1995;164(suppl 15):26.
18. Taylor LM, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991;13:128-136.
19. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
20. Perry IJ, Refseum H, Morrise RW, Ebrahim SB, Ueland PM, Shaper AC. Prospective study of serum total homocysteine concentrations and risk of stroke in middle aged British men. Lancet 1995;346:1395-1398.
21. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systematic lupus erythematosus. Lancet. 1996;348:1120-1124.
22. Wald NJ, Law M, Watt H, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343:75-79.
23. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance chromatography with fluorescent detection. J Chromatogr. 1987;422:43-52.
24. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high performance liquid chromatography assay for total homocysteine levels in human serum. J Chromatogr. 1991;565:441-446.
25. von Eckardstein A, Manilow MR, Upson B, et al. Effects of age, lipoproteins and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 1994;14:460-464.
26. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Artery Dis. 1990;1:215-220.
27. Lolin YI, Sanderson JE, Cheng SK, et al. Hyperhomocysteinaemia and premature coronary artery disease in the Chinese. Heart. 1996;76:117-122.
28. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775-1781.
29. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.
30. Easton DF, Peto J, Babiker AGAG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 1991;10:1025-1035.
31. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal medial thickening and plasma homocysteine in asymptomatic adults: the Atherosclerosis Risk in Communities Study. Circulation. 1993;87:1107-1113.
32. Selhub J, Jacques PF, Boston AG, et al. Association between plasma homocysteine concentration and extracranial carotid artery stenosis. N Engl J Med. 1995; 332:286-291.
33. Verhoef P, Stampfer MJ. Prospective studies of homocysteine and cardiovascular disease. Nutr Rev. 1995;33:283-288.
34. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reducing serum cholesterol lower the risk of ischaemic heart disease? BMJ. 1994;308: 367-372.
35. Kahn HA. The Dorn study of smoking and mortality among US veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr. 1966;19: 1-125.
36. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med. 1992;152:56-64.
37. Green R, Jacobsen DW. Clinical implications of hyperhomocysteinemia. In: Bailey L, ed. Folate in Health and Disease. New York, NY: Marcel Decker; 1995:75-122.
38. Kang SS, Wong PWK, Susmando A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48:536-545.
39. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofoate reductase. Nat Genet. 1995;10:111-113.
40. Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995; 346:1070-1071.
41. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
42. Harmon DL, Woodside JV, Yarrell JWG, et al. The common "thermo-labile" variant of methylene-tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia, QJM. 1996;89:571-577.
43. Kang SS, Wong PWK, Zhou J, Sora J, Lessick M, Grcevich G. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism. 1988;37:611-613.
44. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88:1463-1469.
45. Engbersen AMT, Franken DG, Boers HG, Stevens EMB, Trijbels FJM, Blom HK. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56:142-150.
46. Gallagher PM, Meleady R, Shields DS, et al. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation. 1996;94:2154-2158.
47. Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM. 1996;89:437-444.
48. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase, polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410-2416.
49. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
50. Deloughery TG, Evans A, Sadeghi A et al. Common mutation in methylenetetrahydrofolate reductase. Circulation. 1996;94:3074-3078.
51. 677 T mutation. Arterioscler Thromb Vase Biol. 1996;16:878-882.
52. Harker LA, Slighter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537-543.
53. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Arteriosclerosis. 1975;22:215-227.
54. Harker LA, ROSS R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin lnvest. 1976;58:731-741.
55. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res. 1980; 18:113-121.
56. Brattstrom L, Israelsson B, Worrying B, etal. Impaired homocysteine metabolism in early onset cerebral and peripheral occlusive arterial disease: effect of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51-60.
57. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid: an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48: 215-221.
58. Ubbink JB, Hayward Vermaak WJ, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hypercysteinemia in humans. J Nutr. 1994;124:1927-1933.
59. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12. folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet. 1995;346:85-89.
60. Landgren P, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine lowering effect of folic acid. J Intern Med. 1995;237:381-388.
61. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, Scott JM. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJM. 1997;90:519-524.
62. Cuskelly GJ, McNulty H, McPartlin JM, Strain JJ, Scott JM. Plasma homocysteine response to folate intervention in young women. Ir J Med Sci. 1995;164:3.
63. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.